Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
347
resultados
Última actualización
27/07/2026 [09:40:00]
Resultados 300 a 325 de 347
Resumen de: EP4242304A2
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.
Resumen de: WO2022020388A1
Described herein are methods for assessing likelihood of response of subjects to activatable therapeutic agents and compositions, kits, and methods of preparing and using activatable therapeutic agents. Also described herein are methods for assessing likelihood of response of subjects to activatable therapeutic agents. In some cases, the activatable therapeutic agents of the compositions, kits, and methods disclosed herein can comprise a mammalian protein-derived sequence.
Resumen de: WO2025056488A1
A method for determining a subject's analyte level is disclosed. The method comprises the steps of: • a) non-invasively detecting a first amount of at least one first volatile organic marker originating from a first source of the subject; • b) non-invasively detecting a second amount of at least the first volatile organic marker originating from a second source of the subject, wherein the second source is different from the first source; and • c) determining the subject's analyte level based on the first amount and on the second amount.
Resumen de: WO2024231251A1
The present invention relates to antibodies or antigen-binding fragments thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibodies, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibodies or antigen-binding fragments. Further, it relates to a composition comprising said antibodies or antigen-binding fragments, said polynucleotide, said vector and/or said host cell. Further, it relates to said antibodies or antigen-binding fragments, said polynucleotide, said vector, said host cell and/or said composition for use in medicine and/or for use in the prevention and/or treatment and/or alleviation and/or detection and/or diagnosis of a disease or disorder susceptible to treatment with an inhibitor of IL-1α, IL-1β, IL-33, IL-36α, IL-36β and/or IL- 36γ signaling, optionally wherein the disease or disorder is associated with cells expressing IL1RAP.
Resumen de: WO2024229437A2
Transplantation of inhibitory neuron progenitors rekindles a targeted, time-limited phase of critical period plasticity within recipient brain areas. This restoration of youthful plasticity establishes a therapeutic environment conducive to circuit reorganization, consistently demonstrated to ameliorate cognitive and functional impairments. Remarkably, the mere overexpression of Calb1 in adult inhibitory neurons via viral vectors is adequate to reactivate critical period plasticity without the need for transplantation. Consequently, methodologies and compositions for augmenting Calb1 expression as a therapeutic avenue to reactivate plasticity are described herein.
Resumen de: WO2024228056A1
A universal biomarker array enables the diagnosis and localization of earlier-than- now recognizable disease states as well as increasing the accuracy of diagnosing states of disease(s) in general. The universal biomarker array is formed of a range of mathematical parameters computed from digital tissue images showing tissue details at a cellular level. The universal biomarker array includes one or more novel parameter arrays (namely, a spatial entropy array, a bin array, and/or a quartile array) in combination with one or more state-of-the-art parameter arrays (namely, a pattern array, a distance array, and/or a morphology array) and/or in combination with one or more other parameters. An AI/ML system can be used to analyze the universal biomarker array relative to database-based reference data for early diagnosis and localization of disease processes.
Resumen de: WO2024226596A1
Systems, devices, and techniques are configured to leverage acoustic-based microfluidic amplification for the detection of a biological substance, such as misfolded proteins associated with a protein-misfolding disease. In one example, a system (100) includes a housing defining a main channel (104) configured to contain a fluid solution containing a sample including a plurality of proteins and one or more side channels (106) in fluid communication with the main channel, wherein each side channel of the one or more side channels are configured to establish a liquid-gas interface (108) between the fluid solution in the main channel and air contained in the one or more side channels. The systems may also include at least one acoustic generation element configured to generate acoustic waves within the air of the one or more side channels that causes vibration of the liquid-gas interface and mixing of the fluid solution within the main channel.
Resumen de: WO2024223741A1
Disclosed herein is a method for screening a biological fluid sample for an analyte associated with proteinopathy which relies on a signal that is quadratically proportional to a mass difference generated by molecular interactions of a plurality of first molecular recognition elements (10) and a plurality of second molecular recognition elements.
Resumen de: CN122130951A
本发明涉及一种p‑Tau262检测试剂盒及其应用，尤其适用于对早期阿尔茨海默病的精准诊断，本发明p‑Tau262检测试剂盒包括：第一抗体：第一抗体为p‑Tau262特异性抗体；检测试剂：检测试剂包括第二抗体或特异性识别外泌体膜结构的脂质探针，其中，第二抗体与第一抗体识别不同的p‑Tau262抗原表位。本发明通过采用识别不同表位的p‑Tau262特异性抗体组合或搭配外泌体膜探针，不仅实现了对靶标的高灵敏度、高通量检测，解决了现有血液标志物在共病人群中特异性不足的行业痛点。
Resumen de: MX2026005109A
The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Resumen de: MX2026004613A
Provided a re antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.
Resumen de: MX2025013978A
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: MX2026005100A
The present invention provides a method for determining a biological age, mortality risk and/or probability of a healthy lifespan of a dog; said method comprising: a) determining a biological age, mortality risk and/or probability of a healthy lifespan of the dog using the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and/or red blood cell count; and b) determining a biological age, mortality risk and/or probability of a healthy lifespan for the dog using a DNA methylation profile from the dog.
Resumen de: MX2026004064A
The present invention relates to a NLRP3 variant comprising at least a partial deletion of the PYD. The present invention further relates to a method of screening for a compound that inhibits the NLRP3 inflammasome. The present invention further provides a method comprising the step of administering a compound identified by such a screening method to a subject with a NLRP3-associated inflammatory disorder.
Resumen de: MX2026002775A
The present disclosure relates in some aspects to methods and compositions for detecting an amyloid-related disease in an individual.
Resumen de: MX2026005741A
Provided herein are methods for predicting characteristics, such as activity, function and/or differentiation state of an in vitro population of neuronal cells, for instance a population of neuronal progenitor cells, as well as methods for selecting and/or implanting an in vitro population of neuronal progenitor cells having desired characteristics. Also provided herein are computing devices for performing the provided methods as well as related compositions, articles of manufacture, and kits, including for use in methods of treating a subject having a neurodegenerative disease, for instance Parkinson's disease.
Resumen de: AU2024347751A1
The present invention provides various biomarkers for identifying patients that are likely to benefit from treatment with a TLR inhibitor.
Resumen de: CN122104938A
本发明涉及湖羊FGF1基因及其编码蛋白的应用，属于生物技术领域。湖羊FGF1基因及其编码蛋白在调控湖羊卵巢颗粒细胞氧化应激水平、细胞凋亡或细胞增殖中的应用。本发明首次系统鉴定了绵羊FGF1基因的CDS及蛋白质序列，并分析了其理化性质、翻译后修饰位点、二级与三级结构及系统进化关系，为揭示该基因在氧化应激与细胞命运调控中的作用提供了分子基础。此外，所披露的序列信息及变异数据有助于评估种群遗传多样性，对动物遗传资源的保护、开发与进化研究具有重要科学价值。
Resumen de: CN122109511A
0001 本发明属于神经内科疾病的辅助诊断技术领域，公开了一种神经内科用脑脊液取样检测装置，包括中和筒、酸化筒、储气筒与固定架，固定架上设置有存样组件；中和筒内腔设置有进气管，中和筒顶部设置有密封盖，密封盖上与进气管进气端均设置有单向阀；酸化筒顶部与中和筒底部连接，酸化筒底部设置有针管，且针管顶部设置有单向阀，酸化筒侧面的主气管通过连接座与储气筒连接；储气筒通过气筒接口与连接座连接，储气筒内储存有一定量的惰性气体，储气筒内设置有活塞；通过推注及回抽储气筒，即可完成排除空气、抽吸样本、吹扫硫化氢气体等流程，操作简单方便，提供良好的反应环境；中和筒与酸化筒结构简单，可作为一次性耗材使用，无需清洗。
Resumen de: CN122108723A
本发明涉及一种神经退行性疾病中tau蛋白质变体的富集及鉴定方法。在该方法中，首先设计合成了一种对tau蛋白保守区域具有良好靶向性的识别肽功能化的磁球，将该磁球用于细胞或组织内tau蛋白的富集，然后将所得的tau蛋白样品采用top‑down和middle‑down策略进行神经退行性疾病中tau蛋白质变体的鉴定。
Resumen de: CN122104715A
本发明公开了针对异质核核糖核蛋白hnRNPA2B1的特异性核酸适配体及应用，属于核酸适配体技术领域。所述hnRNPA2B1适配体为通过体外指数富集配体系统进化（SELEX）从设计的寡核苷酸文库中筛选出来的小单链DNA，由80个核苷酸组成，并且对其靶标具有高亲和力。其可在hnRNPA2B1蛋白的检测方法或检测产品，以及靶向调控的药品或生物制剂中应用，具体的可制成分子探针、作为检测试剂、作为靶向制剂等用于hnRNPA2B1蛋白相关疾病诊断治疗。本发明的hnRNPA2B1适配体具有强的亲和力和特异性，相较抗体具有生产成本低、稳定、合成方便、易于修饰等优势，是疾病诊断治疗中抗体的潜在替代品。
Resumen de: CN122109545A
0001 本发明公开了CXCL12或CXCR4作为靶点在制备治疗脑小血管疾病的药物中的应用，通过检测CXCL12或CXCR4表达水平，可以预测脑小血管疾病；还公开了CXCL12或CXCR4作为脑小血管疾病诊断标记物的应用，所述CXCL12或CXCR4抑制剂包括盐酸普乐沙福 Plerixafor。本发明揭示了CXCL12或CXCR4作为脑小血管疾病标志物及治疗靶点的新用途，为其抑制剂的临床转化提供了重要依据。
Resumen de: WO2024236179A1
The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.
Nº publicación: CN122109551A 29/05/2026
Solicitante:
大连理工大学
Resumen de: CN122109551A
0001 本发明公开了一种双亲和肽夹心复合物及其构建方法和应用，属于医药技术领域。所述双亲和肽夹心复合物包括特异性识别Aβ40的亲和肽A1和A2以及特异性识别Aβ42的亲和肽P1和P2，所述亲和肽A1和A2的氨基酸序列分别如SEQ ID NO.1和SEQ ID NO.2所示，所述亲和肽P1和P2的氨基酸序列分别如SEQ ID NO.3和SEQ ID NO.4所示。基于此，采用双亲和肽夹心策略构建检测体系，实现对Aβ40和Aβ42的高特异性、高灵敏度检测和区分。本发明筛选出的亲和肽具有亲和力高、特异性强等特点，为临床上阿尔茨海默病的早期诊断、病情监测及相关靶向检测技术的研发提供了新方向和技术支撑。
BOPI
Sede Electrónica
